Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
Bristol-Myers Squibb Company
The mission of EIIR Trend is to help EIIR buyers in their journey with data, information, and knowledge.
Copyright © 2022. EIIR Trend
This data is based on secondary research and our estimates. No claim is made for authenticity and correctness. If you find any discrepancy please write to firstname.lastname@example.org.